|
Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer. |
|
Cristina Suarez Rodriguez |
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer; Sanofi |
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Ipsen; Pfizer; Roche/Genentech |
Research Funding - AB Science (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Deciphera (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Oncology (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Millennium (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche |
|
|
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess |
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess |
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech |
|
|
Honoraria - Ipsen; Scancell Ltd. |
Consulting or Advisory Role - Ipsen; Scancell Ltd. |
Speakers' Bureau - BMS Brazil; Pfizer |
Research Funding - Scancell Ltd. |
Travel, Accommodations, Expenses - BMS Brazil; Ipsen; Merck |
|
|
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Novartis; Pierre Fabre |
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; BMS Brazil; Janssen; MSD; Pfizer; Roche; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Bayer; BMS Brazil; Janssen; MSD; Pfizer; Roche |
Research Funding - MSD (Inst); Pfizer (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; BMS Brazil; Clovis Oncology; Ipsen; Janssen; Novartis |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Achilles Therapeutics; Bristol-Myers Squibb; Evelo Therapeutics; GlaxoSmithKline; Octimet (Inst) |
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); Adaptimmune (Inst); Agalimmune (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immutep (Inst); Incyte (Inst); Janssen (Inst); kinex (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); MSD (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Pfizer (Inst); Redx Pharma (Inst); Roche (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Takeda (Inst); Tarveda Therapeutics (Inst) |
Travel, Accommodations, Expenses - GlaxoSmithKline |
Other Relationship - iMatch |
|
|
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer |
Consulting or Advisory Role - Bristol-Myers Squibb |
Research Funding - Eisai (Inst); Merck (Inst); Roche (Inst); Viralytics (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Ipsen; Janssen; Roche |
|
Gopalakrishnan Srinivasan |
No Relationships to Disclose |
|
Maria Jose José Mendez Vidal |
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Novartis; Pfizer; Roche; Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Janssen-Cilag; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Merck (Inst); Roche/Genentech (Inst) |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Ferring; Gerson Lehrman Group; Janssen Research & Development; MERCK; Novartis; Pfizer; Roche/Genentech; Seattle Genetics/Astellas |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Incyte; Ipsen; Merck; Novartis; Novartis; Pfizer; Seagen |
Research Funding - AstraZeneca/MedImmune; Roche/Genentech |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Ferring; MSD; Novartis/Ipsen; Pfizer; Research to Practice; Roche/Genentech |